COMMITMENTS AND CONTINGENCIES (Tables)

3 Months Ended

Mar. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contingent Consideration

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the three months ended March 31, 2022 and March 31, 2021 is as follows (in thousands):

Three Months Ended March 31, 2022	Contingent Consideration Liability Related to Acquisition of:
	Arkis				Location in Financial Statements	Derma Sciences		ACell Inc.  (See Note 2)				Location in Financial Statements
	Short-term		Long-term			Long-term		Short-term		Long-term
Balance as of January 1, 2022	$	3,691	$	11,408		$	230	$	—	$	21,800
Transfers	59		(59)			—		4,885		(4,885)
Change in fair value of contingent consideration liabilities	—		$	(1065)	Research and development	—		—		300		Selling, general and administrative
Balance as of March 31, 2022	$	3,750	$	10,284		$	230	$	4,885	$	17,215

Three Months Ended March 31, 2021	Contingent Consideration Liability Related to Acquisition of:
	Arkis				Derma Sciences		ACell Inc.  (See Note 2)		Location in Financial Statements
	Short-term		Long-term		Long-term		Long-term
Balance as of January 1, 2021	$	3,415	$	11,746	$	230	$	—
Additions from acquisition of ACell	—		—		—		23,900
Change in fair value of contingent consideration liabilities	17		265		—		—		Research and development
Balance as of March 31, 2021	$	3,432	$	12,011	$	230	$	23,900